Patents by Inventor Pierre Casellas

Pierre Casellas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitor of protein synthesis, process for its isolation, its use and pharmaceutical compositions in which it is present
    Patent number: 5037960
    Abstract: The present invention relates to a novel glycoprotein, extracted from the seeds of Trichosanthes kirilowii, called: trichokirin, as well as to its modified derivatives containing a free or blocked SH group.It relates to a process for its preparation, to its use and to pharmaceutical compositions in which it is present.
    Type: Grant
    Filed: July 14, 1987
    Date of Patent: August 6, 1991
    Assignee: Sanofi
    Inventors: Luigi Barbieri, Pierre Casellas, Fiorenzo Stirpe
  • Immunotoxins, process for their preparation and pharmaceutical compositions in which they are present
    Patent number: 4981953
    Abstract: The present invention relates to the immunotoxines which are obtained by the covalent coupling of, on the one hand, trichosanthin or trichokirin, as such or appropriately modified with, on the other hand, an antibody or antibody fragment, used in its natural form or correctly modified, which is capable of selectively recognizing an antigen carried by the target cells to be destroyed.
    Type: Grant
    Filed: July 14, 1987
    Date of Patent: January 1, 1991
    Assignee: Sanofi
    Inventors: Luigi Barbieri, Pierre Casellas, Fiorenzo Stirpe
  • Process for the potentiation of immunotoxins
    Patent number: 4919927
    Abstract: The present invention relates to a process for potentiating the activity of a conjugate consisting of the A chain of ricin coupled with an antibody directed against human T cells, the said process consisting in adding an effective quality of ammonium chloride to the said conjugate.
    Type: Grant
    Filed: August 31, 1988
    Date of Patent: April 24, 1990
    Assignee: Sanofi
    Inventors: Pierre Casellas, Pierre Gros, Franz Jansen
  • Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
    Patent number: 4911911
    Abstract: Glycoprotein (GPIR) the ribosome-inhibiting activity of the native GPIR and having a prolongedaction in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous blocking of the oxidation product by formation of a Schiff's base with a suitable primary amine. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin.
    Type: Grant
    Filed: December 15, 1986
    Date of Patent: March 27, 1990
    Assignee: Sanofi
    Inventors: Pierre Casellas, Bernard Bourrie, Xavier Canat
  • Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
    Patent number: 4911912
    Abstract: Glycoprotein (GPIR) having the ribosome-inhibiting activity of the native GPIR and having a prolonged-action in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous reduction with cyanoborohydride ions. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin having a prolonged-action in vivo.
    Type: Grant
    Filed: December 15, 1986
    Date of Patent: March 27, 1990
    Assignee: Sanofi
    Inventors: Pierre Casellas, Bernard Bourrie, Xavier Canat
  • Pharmaceutical composition comprising a combination of at least one immunotoxin and at least one mannose-containing polymer
    Patent number: 4749566
    Abstract: The invention relates to pharmaceutical compositions comprising a combination of at least one immunotoxin and at least one mannose-containing polymer. This combination makes it possible to inhibit the rapid elimination of immunotoxins from the plasma after injection.
    Type: Grant
    Filed: November 26, 1985
    Date of Patent: June 7, 1988
    Assignee: Sanofi
    Inventors: Pierre Casellas, Bernard Bourrie, Pierre Gros
  • Anti-cancer drugs for the treatment of leukaemias I, constituted by the chain A of ricin and a specific monoclanal antibody
    Patent number: 4643895
    Abstract: The present invention relates to an anti-cancer drug, characterized in that it contains at least one product constituted by the chain A of recin conjugated by means of a disulfide bridge with at least one fraction of a monoclonal antibody of leukaemic anti-cell specificity, and to the processes for preparing the active ingredient of said drug.
    Type: Grant
    Filed: November 1, 1982
    Date of Patent: February 17, 1987
    Assignee: Sanofi
    Inventors: Pierre Casellas, Pierre Gros, Franz Jansen